The two dosage forms of voriconazole (parenteral and oral) allow sequential therapy with the same active ingredient, as well as a reduction in the number of days of IV therapy at the expense of ...

There was no correlation between initial drug level and weight-adjusted voriconazole dosage (r 2 = 0.01; Figure 2). When a range of 1.0–5.5 mg/L was considered therapeutic, 32 patients (29.6% ...

Phenotype-guided dosing strategies can increase the proportion of patients with hematologic malignancies who achieve a therapeutic drug concentration of prophylactic voriconazole, according to ...

A total of 837 patients (415 assigned to voriconazole and 422 to liposomal amphotericin B) were evaluated for success of treatment. The overall success rates were 26.0 percent with voriconazole ...

Voriconazole is an antifungal agent which has been approved for treatment of a broad range of fungal infections, including those caused by Candida species.

Although voriconazole has been shown to interact with calcineurin inhibitors, this interaction has not been thoroughly examined. The purpose of this study was to evaluate the drug interaction ...

The medicines are indicated for use in patients 12 years of age and older in the treatment of fungal infections, including invasive Aspergillosis, Candidemia in non-neutropenic patients.